RELMADA ACQUIRES NEUROSTEROID FROM ASARINA: Relmada Therapeutics (RLMD) announced Thursday the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma, being developed for ...
A new study led by researchers at UF Health has uncovered why males and females may experience stress differently.
CORAL GABLES, Fla. - Relmada Therapeutics , Inc. (NASDAQ:RLMD), a clinical-stage biotechnology firm with a market capitalization of $11.5 million, has announced the acquisition of Sepranolone, a Phase ...
(RTTNews) - Relmada Therapeutics, Inc. (RLMD), a clinical-stage biotechnology company, on Thursday announced the acquisition of Sepranolone, a Phase 2b-ready neurosteroid, from Asarina Pharma AB.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for central nervous system (CNS) and metabolic disorders. With a commitment to advancing ...
Medical Xpress on MSN10d
UF scientists find key differences in male, female responses to stressA new study led by researchers at UF Health has uncovered why males and females may experience stress differently.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback